NCT01919125View on ClinicalTrials.gov

Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008)

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Hepatitis C, Chronic
Interventions
DRUG

IDX719

IDX719 supplied as 50 mg tablets.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01919125 - Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008) | Biotech Hunter | Biotech Hunter